Patents by Inventor Shoichi Hazama

Shoichi Hazama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10875900
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 29, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Publication number: 20200181195
    Abstract: The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Applicant: NEC CORPORATION
    Inventors: TOMOYA MIYAKAWA, MASAAKI OKA, SHOICHI HAZAMA, KOJI TAMADA, KEIKO UDAKA
  • Publication number: 20200172966
    Abstract: An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR5112 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 4, 2020
    Inventors: Masaaki Oka, Shoichi Hazama, Ryouichi Tsunedomi
  • Publication number: 20200157163
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Application
    Filed: February 5, 2020
    Publication date: May 21, 2020
    Applicant: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Publication number: 20200121772
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 23, 2020
    Applicant: CYTLIMIC INC.
    Inventors: Tomoya Miyakawa, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
  • Publication number: 20200115740
    Abstract: A therapeutic effect of irinotecan is predicted using a predetermined genetic polymorphism. A genetic polymorphism identified by rs1980576 in APCDD1L gene, or a genetic polymorphism in linkage disequilibrium with the above genetic polymorphism is analyzed, and determination is performed based on the genotype of the genetic polymorphism.
    Type: Application
    Filed: June 22, 2018
    Publication date: April 16, 2020
    Applicants: Yamaguchi University, Toyo Kohan Co., Ltd.
    Inventors: Ryouichi Tsunedomi, Shoichi Hazama, Hiroaki Nagano
  • Patent number: 10590179
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: March 17, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10537626
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 21, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10526388
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 7, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10450601
    Abstract: A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: October 22, 2019
    Assignees: Toyo Kohan Co., Ltd., Yamaguchi University
    Inventors: Shuichi Kamei, Mayuko Hosoya, Masaaki Oka, Shoichi Hazama, Ryouichi Tsunedomi
  • Publication number: 20190161791
    Abstract: In the case of using a blocking nucleic acid to prevent non-specific hybridization of a target nucleic acid with a nucleic acid probe, further excellent efficiency of detecting the target nucleic acid is achieved. A buffer composition used in hybridization of a target nucleic acid with a nucleic acid probe, wherein the buffer composition for hybridization contains a blocking nucleic acid comprising a nucleotide sequence complementary to a region comprising at least a non-detection target nucleotide in a non-target nucleic acid, in a concentration of one or more times higher than the concentration of a nucleic acid in a nucleic acid mixture consisting of the target nucleic acid and the non-target nucleic acid.
    Type: Application
    Filed: August 2, 2017
    Publication date: May 30, 2019
    Applicants: TOYO KOHAN CO., LTD., YAMAGUCHI UNIVERSITY
    Inventors: Toshiya TSUDA, Shuichi KAMEI, Mitsuyoshi OBA, Hirofumi YAMANO, Ryouichi TSUNEDOMI, Shoichi HAZAMA, Hiroaki NAGANO
  • Publication number: 20190062389
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 28, 2019
    Applicant: CYTLIMIC INC.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Publication number: 20180237833
    Abstract: An object of the present invention is to provide a simple and efficient device for predicting a risk of occurrence of a side effect of irinotecan by analyzing a single nucleotide polymorphism in a region encoding a specific gene. The prediction of the risk of the occurrence of a side effect of irinotecan is assisted by analyzing a single nucleotide polymorphism in a region encoding the APCDD1L gene, the R3HCC1 gene, the OR5112 gene, the MKKS gene, the EDEM3 gene, or the ACOX1 gene which are present on genomic DNA in a biological sample collected from a test subject; or a single nucleotide polymorphism which is in linkage disequilibrium with or genetically linked to the single nucleotide polymorphism, and determining whether the single nucleotide polymorphism is homozygous for a variant type, heterozygous, or homozygous for a wild-type.
    Type: Application
    Filed: February 16, 2016
    Publication date: August 23, 2018
    Inventors: Masaaki Oka, Shoichi Hazama, Ryouichi Tsunedomi
  • Publication number: 20180169199
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.
    Type: Application
    Filed: October 7, 2015
    Publication date: June 21, 2018
    Applicant: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Publication number: 20180105567
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 11 and consisting of 11 or less amino acid residues.
    Type: Application
    Filed: March 9, 2016
    Publication date: April 19, 2018
    Applicant: CYTLIMIC INC,
    Inventors: Tomoya MIYAKAWA, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
  • Publication number: 20180057531
    Abstract: The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 1, 2018
    Applicant: NEC Corporation
    Inventors: Tomoya MIYAKAWA, Masaaki OKA, Shoichi HAZAMA, Koji TAMADA, Keiko UDAKA
  • Publication number: 20160265037
    Abstract: A buffer composition for hybridization of a target nucleic acid is provided. The nucleic acid can include a nucleotide to be detected with a nucleic acid probe. The probe can contain a nucleotide sequence complementary to the target nucleic acid. The buffer can include a blocking nucleic acid having a nucleotide sequence complementary to a non-target nucleic acid having a nucleotide not to be detected corresponding to the nucleotide to be detected. The buffer composition can suppress non-specific hybridization to the nucleic acid probe even when a non-target nucleic acid is present. The use of the buffer composition can achieve excellent detection efficiency of the target nucleic acid.
    Type: Application
    Filed: September 1, 2014
    Publication date: September 15, 2016
    Applicants: Toyo Kohan Co., Ltd., Yamaguchi University
    Inventors: Shuichi Kamei, Mayuko Hosoya, Masaki Oka, Shoichi Hazama, Ryouichi Tsunedomi